Full-Time
Principal Software Engineer
Platform Engineering
Updated on 8/13/2026
Moderna
5,001-10,000 employees
Develops mRNA-based medicines for health
Compensation Overview
$142.5k - $256.5k/yr
No H1B Sponsorship
Cambridge, MA, USA
Hybrid
70% of work is in-office.
 DevOps & Infrastructure (1) |
|---|
 Software Engineering (1) |
|---|
Get referred to Moderna
See people who can refer or advise you
- At least 10 years of experience in software engineering, platform engineering, DevOps, infrastructure automation, secure software delivery, or a related role.
- Deep software engineering experience designing, implementing, and operating developer platforms, internal tools, infrastructure automation, CI/CD systems, or secure software delivery platforms.
- Very strong programming skills in Python or TypeScript/JavaScript.
- Significant experience with GitHub, GitHub Actions, CI/CD workflows, and modern software delivery practices.
- Significant experience with AWS or another cloud provider for deploying and managing applications or platform services.
- Experience with Docker and containerized applications.
- Strong understanding of secure software development practices, software supply chain, dependency management, vulnerability scanning, artifact management, secrets handling, identity, authorization, and policy enforcement.
- Proven ability to set technical direction and design systems that balance security, standardization, usability, reliability, and developer productivity.
- Proven experience leading technical initiatives with cross-functional stakeholders.
- Demonstrated ability to mentor engineers, raise technical standards, and guide teams through architecture, design, implementation, and operational tradeoffs.
- Expert troubleshooting skills across application code, build pipelines, cloud infrastructure, networking, identity, developer tooling, and third-party platforms.
- Demonstrated ability to adapt to changing team priorities, operate effectively in ambiguous problem spaces, and contribute across a range of platform engineering responsibilities, including areas outside immediate prior experience.
- Design and build secure platform capabilities using Python/TypeScript, GitHub Actions, Pulumi, Docker, AWS, and relevant internal or vendor APIs.
- Lead the design and evolution of AI runtime safety and AI gateway patterns, including policy enforcement, access controls, telemetry, auditability, and operational controls.
- Build and guide implementation of governed AI-assisted development workflows by packaging approved tools, creating reusable integration patterns, improving developer experience, and embedding security and compliance expectations into paved-road delivery workflows.
- Partner with Cybersecurity, Architecture, AI platform teams, and engineering leaders to align on platform standards, adoption strategy, risk posture, and implementation tradeoffs.
- Create and drive adoption of templates, reference implementations, documentation, examples, and paved-road patterns that help application teams adopt secure development and AI-assisted workflows.
- Improve developer experience by identifying systemic friction, reducing setup time, eliminating manual toil, standardizing common workflows, and making secure patterns easy to adopt.
- Establish and mature operational practices for owned capabilities, including monitoring, alerting, dashboards, runbooks, support models, service ownership, and lifecycle management.
- Identify recurring developer pain points and influence the roadmap by proposing improvements to shared frameworks, templates, platform tooling, and paved paths.
- Lead integration of secure software delivery controls into development workflows, including CI/CD guardrails, policy checks, artifact controls, and developer remediation patterns.
- Contribute hands-on across Builder Tools & Platforms priorities as team needs evolve, including developer tooling, platform automation, secure delivery patterns, internal frameworks, and operational support.
- Mentor and coach engineers, raise engineering standards, review designs and implementations, and help teams make durable technical decisions across platform and application boundaries.
- Experience with AI-assisted development tooling, AI gateway patterns, model or API access controls, policy-as-code, telemetry, or runtime safety controls.
- Experience shaping platform strategy or technical roadmaps for capabilities adopted by multiple engineering teams.
- Experience partnering with security, architecture, platform, and application teams to drive adoption of shared capabilities and standards.
- Experience with infrastructure-as-code tools such as Pulumi, CDK, Terraform, or similar.
- Experience with application security, cloud security, software supply chain controls, vulnerability management workflows, or secure CI/CD guardrails.
- Experience building internal developer platforms, paved-road workflows, reusable templates, CLIs, scaffolding systems, or shared engineering standards.
- Experience with Kubernetes, container security, base image lifecycle management, secrets management, network isolation, or secure runtime patterns.
- Experience creating documentation, reference architecture, onboarding materials, and developer enablement content for shared platform capabilities.
Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2010
Get referred to Moderna
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA approved mFLUSIVA on August 5, 2026, unlocking Moderna’s first mRNA flu franchise.
- Moderna began Phase 1 Bundibugyo Ebola testing in Canada on August 4, 2026.
- Management expects mFLUSIVA availability for the 2026–2027 respiratory season and EU, Canada, Australia reviews.
What critics are saying
- mFLUSIVA’s 65-plus accelerated approval requires confirmatory data by 2027; failure threatens labeling.
- Q2 2026 revenue was $145 million, while the $950 million Arbutus settlement crushed earnings.
- If COVID demand keeps falling before flu uptake scales, Moderna’s cash runway tightens sharply.
What makes Moderna unique
- Moderna pioneered FDA-approved mRNA vaccines: Spikevax, mRESVIA, mNEXSPIKE, and mFLUSIVA by August 2026.
- Its mRNA platform compresses vaccine design timelines across respiratory, oncology, and biodefense programs.
- CEPI-backed global manufacturing partnerships extend Moderna’s reach beyond U.S. seasonal vaccine sales.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Sabbatical Leave
Hybrid Work Options
401(k) Company Match
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Jennifer Steinke named Travel Manager of the Year by Business Travel News. Travel director of Moderna also heads think tank for BTE Published on: August 7, 2026 Jennifer Steinke, director of travel, meetings and fleet for Moderna, was named the 2026 Travel Manager of the Year by Business Travel News. The recognition was announced during an award reception in Chicago as GBTA's annual convention came to a close. Steinke also leads the Travel Buyer Think Tank for Business Travel Executive. Steinke, who received five nominations in the lead-up to the final announcement, has leaned hard into artificial intelligence for the Moderna travel program, according to an announcement. She has created within Moderna's internal enterprise AI platforms a large language model interface, behind which sits an AI-first booking tool partner BizTrip.ai, an AI-first data system Cerebri.ai and midsize TMC Cain Travel to serve as a fulfillment partner. Travelers initiate bookings via natural language prompts that return trip options based on company policy and are personalized on dynamic profiles that live in the BizTrip.ai booking tool. Steinke uses internal benchmarking at the point of sale to provide an instant gut check - and sometimes an alert - to travelers about trip costs and how they compare for similar bookings made by Moderna travelers. Critically, said the announcement, the traveler profiles include not only their loyalty numbers with hotel and airline suppliers, but also their loyalty status levels, which have become the linchpin of Steinke's value strategy. She calls it the Policy of One, and the platform she has created is Travel and Meetings Intelligence - or TAMI. Based on a traveler's loyalty status, said the announcement, Steinke has created a model for understanding total trip cost and total itinerary value by creating a matrix of policy-permitted booking permutations and bumping that up against the traveler's loyalty status to understand elements like how lounge access can offset meals, how loyalty might offset extra legroom charges and also allow for the probability of getting an upgrade. The impact of status on baggage fees is accounted for in that matrix and, ultimately, the ability to negotiate and display special amenities and promotions at the point of sale regardless of loyalty status is also baked into the tool.
Moderna (MRNA) stock jumps after FDA finally approves its flu vaccine. Moderna (MRNA) stock rises 3.6% after FDA approval of mFlusiva flu vaccine for adults 50+, but analysts warn revenue won't arrive until 2027. By Trader Edge August 6, 2026 3 Mins Read Tldr. * The FDA approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. * MRNA stock is up 3.6% to $58.30 ahead of the open following the approval. * mFlusiva is Moderna's second commercial mRNA vaccine and fourth FDA-approved product overall. * Analysts don't expect meaningful revenue from mFlusiva until the second half of 2027. * Of 23 analysts covering MRNA, 18 carry a "hold" rating, with a consensus price target of $55.12. Moderna (MRNA) stock is up 3.6% to $58.30 ahead of the open on Wednesday after the FDA approved its mRNA-based seasonal flu vaccine, mFlusiva, for adults aged 50 and older. The approval came late Wednesday and marks Moderna's second commercial mRNA vaccine, extending its respiratory portfolio beyond Covid-19. The stock has had a rough run lately, dropping 31.2% over the past month after pulling back from its July 6 annual high of $85.60. Despite that slide, MRNA is still up 90.8% in 2026 and 104.8% over the past 12 months. The approval follows a bumpy path to clearance. In February, the FDA issued a "refuse-to-file" letter, declining to review the application after Moderna tested the vaccine against a standard flu shot rather than Fluzone High-Dose, the FDA's recommended comparator for older adults. The agency reversed that decision just two days later. By June, an FDA advisory committee voted unanimously to recommend mFlusiva for adults 50 and older. Moderna expects mFlusiva to be available for the 2026-2027 flu season, but the company missed key pre-season contracting cycles. That means analysts are not penciling in meaningful revenue from the vaccine until the second half of 2027. Wall street still cautious. The broader analyst picture remains lukewarm. Of the 23 analysts covering Moderna, 18 carry a "hold" rating. Just two rate it a "strong buy," and two rate it a "strong sell." The 12-month consensus price target sits at $55.12, which is actually a small discount to where the stock is trading right now. Short interest is elevated too. About 14.3% of available float is sold short, with a short ratio of nearly seven days. That suggests a lot of skepticism is still baked into the stock. mRNA platform validation. The approval does carry strategic weight beyond just flu shots. It is a step toward a combined Covid-flu vaccine, a product Moderna pulled from FDA review last year after regulators asked for more data. It also acts as a public validation of Moderna's mRNA platform, which has faced political headwinds. HHS Secretary Robert F. Kennedy Jr. directed the cancellation of roughly $500 million in federal mRNA vaccine contracts in late 2025, citing claims the vaccines caused "new mutations," a claim that is not supported by scientific evidence. Kennedy has said mRNA technology "poses more risks than benefits." Moderna's bottom line is still largely driven by its Covid-19 franchise, including Spikevax and mNEXSPIKE, as its most recent earnings showed. mFlusiva is now Moderna's fourth FDA-approved product and its fifth approved product globally. Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions - all in one powerful platform. Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount. Limited Time Offer Get 3 free stock ebooks. Discover top-performing stocks in AI, Crypto, and Technology with expert analysis. * Top 10 AI Stocks - Leading AI companies * Top 10 Crypto Stocks - Blockchain leaders * Top 10 Tech Stocks - Tech giants
New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine. By LAURAN NEERGAARD AP Medical Writer WASHINGTON (AP) - The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, manufacturer Moderna said. The shot, named mFlusiva, is intended for adults age 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers. While there already are multiple flu vaccine options in the U.S., including three specifically recommended for people age 65 or older, tens of thousands of Americans die from influenza every year and older adults are among the most vulnerable. Flu vaccines must be updated annually to best match circulating strains of the virus. Vaccines made with the Nobel Prize-winning mRNA technology are faster to manufacturer than other types, and experts say this additional option might help if the shape-shifting flu virus mutates in a way that requires suddenly brewing new doses. Moderna, which is based in Cambridge, Massachusetts, said the FDA granted full approval for mFlusiva's use in people ages 50 to 64, based on a study of 40,000 people that found the new shot reduced flu cases by about 27% compared with another routinely used flu vaccine brand. For people 65 or older, the biotech and pharmaceutical company said the FDA granted what's called accelerated approval for the shot - based on a smaller study showing it generated a strong immune response compared with an existing high-dose vaccine for seniors - while it conducts an additional postmarketing study. Moderna's data showed no major safety issues although the shot did cause some temporary reactions including injection site pain, fever, headache, tiredness and aches that occurred somewhat more than with today's flu shots. The FDA action comes after a highly unusual public dispute over mFlusiva earlier this year. A then-top FDA official blocked the company's application, a sign of the agency's heightened vaccine scrutiny under Health Secretary Robert F. Kennedy Jr. Days later, the agency changed course after Moderna publicly challenged the ruling - and in June a panel of independent advisers to the FDA unanimously recommended the vaccine's approval. Follow the AP's coverage of the U.S. Food and Drug Administration at https://apnews.com/hub/Wmconnect-food-and-drug-administration. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. 08/06/2026 08:43 -0400 News, photo and web search.
Moderna begins first human trial of Bundibugyo Ebola vaccine. Published: August 04, 2026 at 2:10PM EDT Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and currently has no approved vaccine. Health Canada has cleared an early-stage study and the first volunteers have already received the shot, called mRNA-1469, acording to the vaccine maker. The experimental shot uses the same mRNA technology behind Moderna's COVID-19 vaccine. The trial, which will run at three sites in Canada, aims to enroll about 80 healthy adults to check if the vaccine is safe and triggers an immune response. The work is part of an expanded partnership with the Coalition for Epidemic Preparedness Innovations, or CEPI, which has pledged up to US$50 million to help fund the vaccine's early testing and manufacturing. The Bundibugyo strain is driving an outbreak in Democratic Republic of Congo that has become the world's second-largest Ebola outbreak on record, with 3,748 confirmed cases and 1,657 confirmed deaths reported as of August 1, according to the U.S. Centers for Disease Control and Prevention data. The cases are increasing faster than during the 2014-2016 West Africa Ebola epidemic, which was the largest on record, said CEPI chief executive Richard Hatchett. The World Health Organization and Africa CDC have both declared the current outbreak a public health emergency. If the vaccine is eventually approved, Moderna said it plans to make at least 500,000 doses available to low- and middle-income countries at access pricing under its agreement with CEPI. Reporting by Kamal Choudhury in Bengaluru; Editing by Jonathan Ananda.
Health Canada authorizes Moderna clinical trial for new Ebola vaccine candidate. By Nicole Ireland, The Canadian Press Posted Aug 4, 2026 11:41 am. Health Canada has authorized Moderna to conduct a clinical trial on a new mRNA vaccine that targets the form of Ebola blamed for the largest outbreak ever reported in the Democratic Republic of Congo. There is no vaccine or treatment for the Bundibugyo type of Ebola, which has killed more than 1,700 people in Congo. Ebola has never been detected in Canada but it will be the first country to participate in Moderna's trial in a global race to develop a vaccine. Participants are healthy adults and will not be exposed to the virus to test the vaccine. A spokesperson for Moderna says the first volunteer in the trial received the shot on Monday in Truro, N.S., and that the company expects to enrol 80 people in Truro, Halifax and Toronto. The Phase 1 trial will evaluate the vaccine's safety, determine the right dosage, monitor for side effects and study the antibody response. Health Canada said in a release issued Tuesday that the department authorized the clinical trial on July 30. The United Kingdom has also started a clinical trial for a Bundibugyo virus vaccine, made by the University of Oxford. Health Canada said Moderna would need to do Phase 2 and 3 clinical trials to determine the vaccine's effectiveness before it could seek authorization for wider use. "Any final submission would need to meet Health Canada's stringent safety, efficacy and quality standards before the vaccine could be allowed on the Canadian market," the department's news release said. Ebola is spread through unprotected contact with the bodily fluids of people sick with the virus or who have died from it. Ebola is a filovirus, which can cause severe hemorrhagic fever. Moderna's executive director of global health security and R&D partnerships said Canada was chosen for the first clinical trial "based on Moderna's experience conducting early-phase trials there, Health Canada's regulatory oversight, and the country's long-standing contributions to filovirus research." "Canadian researchers and participants are contributing an important first step in a broader international effort to develop a vaccine against a form of Ebola for which no approved protection is currently available," Hamilton Bennett said in an emailed statement. The Bundibugyo form of Ebola was first declared an outbreak on May 15 and has spread in Congo and neighbouring Uganda. The World Health Organization has deemed it a public health emergency of international concern. With files from The Associated Press Keep it Factual Add CityNews Calgary as a trusted source on Google to see more local stories from us.